Patents for A61P 35 - Antineoplastic agents (221,099)
07/2009
07/15/2009EP2077829A2 Pai-1 binding modulators for the treatment of ocular disorders
07/15/2009EP2005954A9 Kit for cancer therapy and pharmaceutical composition for cancer therapy
07/15/2009EP1517989B1 Method for the diagnosing of sphingolipid metabolism
07/15/2009EP1458726B1 Mitotic kinesin inhibitors
07/15/2009EP1328263B1 Process of making and method of use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa cells
07/15/2009EP1268802B1 Beta-like glycoprotein hormone polypeptide and heterodimer
07/15/2009EP1214097B1 Nucleic acids encoding polyepitope polypeptides
07/15/2009EP1141015B1 Insulin-like growth factor (igf) i mutant variants
07/15/2009CN101481405A Somatostatin-dopamine chimeric analogs
07/15/2009CN101481359A Cyclic protein tyrosine kinase inhibitors
07/15/2009CN100513565C Apoptin-associating protein
07/15/2009CN100513404C Novel compunds, pharmaceutical compositions containing same, and methods of use for same
07/15/2009CN100512879C Conjugate having cleavable linkage for use in liposome
07/15/2009CN100512842C Disinfectant
07/15/2009CN100512811C Hepatoprotective activity of 10-o-p-hydroxybenzoyiaucubin
07/15/2009CN100512807C Pharmaceutical for preventing and curing acute gout, tumor and hepatic/pulmonary fibrosis and preparation method thereof
07/15/2009CN100512805C Sesquiterpene injection, preparing method and use thereof
07/15/2009CN100512803C Natural carotene soft capsule and its production method
07/14/2009US7560591 Benzamidine derivatives having anti-inflammatory and immunosuppressive activity
07/14/2009US7560569 (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile, for treating type II diabetes; increase glucagon-like peptide activity
07/14/2009US7560558 quinoline pyridyl derivatives antagonist; antitumor agents; renal disease, hepatic fibrosis, cirrhosis, fibroid lung, scleroderma, wound healing, arthritis, congestive cardiac disease, ulcer, ocular disorder, cornea disorder, diabetic nephropathy
07/14/2009US7560552 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
07/14/2009US7560551 Aurora kinase modulators and method of use
07/14/2009US7560546 Tyrosine kinase inhibitors
07/14/2009US7560543 Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
07/14/2009US7560540 Nucleotide sequences coding B7 immune response regulatory protein selectively expressed on dendritic cells for use as therapeutic tool in targeting viral and tumor cell for destruction
07/14/2009US7560527 Modified adenovirus fibre and uses
07/14/2009US7560490 Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
07/14/2009US7560466 N4-(2,2-Dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-N2-(3-chloro-4-methoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for IgE (Fc epsilon RI) and IgG (Fc gamma RI) antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis
07/14/2009US7560462 Compounds useful for inhibiting CHK1
07/14/2009US7560461 Quinazoline derivatives as kinase inhibitors
07/14/2009US7560442 For prophylaxis and therapy of diabetes mellitus Type I and Type II, inflammation, cancer, necrosis, gastric ulcers, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease), neuropathic diseases, neuropathic pain and polyneuropathy
07/14/2009US7560440 Endothelial growth factors; antiischemic agents; neovascularization
07/14/2009US7560435 Therapeutic use of riboside of 5-aminoimidazole-4-carboxamide (acadesine)
07/14/2009US7560253 Detecting level of expression of a hemopoietic linkage switch-5 (HLS-5) polynucleotide in a biological sample from a suspected or known cancer patient
07/14/2009US7560110 Radioimmunotherapy; antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct
07/14/2009US7560106 cleaving a heparin-like glycosaminoglycan using modified heparinases having altered binding specificity and activity; angiogenesis inhibition
07/14/2009CA2543665C Cci-779 for treating mantle cell lymphoma
07/14/2009CA2403321C Amide compounds and use thereof
07/14/2009CA2382302C A nucleic acid and encoding polypeptide for use in inhibiting tumor angiogenesis
07/14/2009CA2366754C Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
07/14/2009CA2242542C Compositions and methods for therapeutic use
07/10/2009WO2008083367A2 Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
07/10/2009CA2710234A1 Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
07/09/2009WO2009086516A1 Anti-proliferative compounds and their use
07/09/2009WO2009086440A1 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin d analogs
07/09/2009WO2009086439A2 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs
07/09/2009WO2009086436A1 (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
07/09/2009WO2009086324A1 Anti-hedgehog antibodies
07/09/2009WO2009086264A1 Benzofuropyrimidinones as protein kinase inhibitors
07/09/2009WO2009086204A2 Methods for treating neuropsychiatric conditions
07/09/2009WO2009086201A1 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents
07/09/2009WO2009086192A1 Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
07/09/2009WO2009086108A1 Stable elsamitrucin salt formulations
07/09/2009WO2009085983A1 5-anilinoimidazopyridines and methods of use
07/09/2009WO2009085980A1 8-anilin0imidaz0pyridines and their use as anti-cancer and/or anti-inflammatory agents
07/09/2009WO2009085920A1 Fdf03 antibodies and uses thereof
07/09/2009WO2009085913A1 PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS
07/09/2009WO2009085262A1 Method of treating cancer with immunomodulatory compounds and igg
07/09/2009WO2009085230A1 Inhibitors of pi3 kinase
07/09/2009WO2009085209A2 Methods for using and identifying modulators of delta-like 4
07/09/2009WO2009085185A1 Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
07/09/2009WO2009084982A1 Use of organic dyes as an agent for treating oncological diseases
07/09/2009WO2009084739A1 Method and pharmaceutical composition for treatment of cancer using bmp10 protein,
07/09/2009WO2009084738A1 Method and pharmaceutical composition for treatment of cancer using bmp9 protein
07/09/2009WO2009084695A1 2-aminoquinazoline derivative
07/09/2009WO2009084693A1 Antitumor agent
07/09/2009WO2009084680A1 Gold nanoparticle composition, dna chip, near infrared absorbent, drug carrier for drug delivery system (dds), coloring agent, biosensor, cosmetic, composition for in vivo diagnosis and composition for therapeutic use
07/09/2009WO2009084671A1 Human anti-α9 integrin antibody
07/09/2009WO2009084668A1 Method of inhibiting cancer cell proliferation, proliferation inhibitor and screening method
07/09/2009WO2009084482A1 Composition comprising sesamin component and quercetin glycoside
07/09/2009WO2009084216A1 Oral powder and granular antitumor agent
07/09/2009WO2009083755A1 Use of t cells expressing cd16 receptors for enhancing the antibody-dependent cellular cytotoxiciy (adcc)
07/09/2009WO2009083738A2 Rna delivery vehicles
07/09/2009WO2009083614A1 Hydroxy-bisphosphonic acid derivatives as vector for targeting bone tissue
07/09/2009WO2009083232A1 Parvovirus cancer therapy and combination with chemotherapy
07/09/2009WO2009083076A1 2-benzylpyridazinone derivatives as met kinase inhibitors
07/09/2009WO2009083042A1 Methods and means for the treatment of cancer
07/09/2009WO2009083009A2 Monoclonal antibodies against cd32b
07/09/2009WO2009082817A1 Silencing of polo-like kinase expression using interfering rna
07/09/2009WO2009066955A3 Lyophilized pharmaceutical composition with improved stability containing taxane derivatives, and method of manufacturing the same
07/09/2009WO2009057795A3 Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
07/09/2009WO2009043524A3 Use of a peptide as therapeutic agent
07/09/2009WO2009037705A3 Esters of n-phenylanthranilic acid for use in the treatment of cancer and inflammation
07/09/2009WO2009033814A3 Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
07/09/2009WO2009033806A3 Use of gly-pro-glu-oh (gpe) as a therapeutic agent
07/09/2009WO2009033764A3 Use of a peptide as a therapeutic agent
07/09/2009WO2009033749A3 Use of thymopentin as a therapeutic agent
07/09/2009WO2009033748A3 Use of osteostatin, alone or in combination with thymopentin, as a therapeutic agent
07/09/2009WO2009020933A9 Therapeutic use of anti-tweak receptor antibodies
07/09/2009WO2009012096A3 Improved therapeutic methods and compositions comprising chroman ring compounds
07/09/2009WO2008151833A3 Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
07/09/2009WO2008147864A3 Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
07/09/2009WO2008138889A8 3, 6-disubstituted-imidazo [1, 2-b] pyridazines and 3, 5-disubstituted pyrazolo[1, 5-a] pyrimidines as phosphatidylinositol-3-kinase inhibitors
07/09/2009WO2008136976A3 Compounds for treating proliferative disorders
07/09/2009WO2008090355A3 Inhibitors of stem cells markers
07/09/2009WO2008054431A3 Anti-hyperproliferative therapies targeting hdgf
07/09/2009WO2008040190A8 Small peptides for anti-angiogenesis and use thereof
07/09/2009WO2007098548A8 A molecule and chimeric molecules thereof
07/09/2009US20090178148 Compositions and methods for modifying the content of polyunsaturated fatty acids in mammalian cells